0001209191-22-050525.txt : 20220919
0001209191-22-050525.hdr.sgml : 20220919
20220919163015
ACCESSION NUMBER: 0001209191-22-050525
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220919
FILED AS OF DATE: 20220919
DATE AS OF CHANGE: 20220919
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCIASCIA THOMAS
CENTRAL INDEX KEY: 0001229946
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38886
FILM NUMBER: 221250907
MAIL ADDRESS:
STREET 1: 39 OLD RIDGEBURY RD. SUITE 11
CITY: DANBURY
STATE: CT
ZIP: 06810
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Trevi Therapeutics, Inc.
CENTRAL INDEX KEY: 0001563880
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 450834299
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 195 CHURCH STREET
STREET 2: 14TH FLOOR
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-304-2499
MAIL ADDRESS:
STREET 1: 195 CHURCH STREET
STREET 2: 14TH FLOOR
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-19
0
0001563880
Trevi Therapeutics, Inc.
TRVI
0001229946
SCIASCIA THOMAS
C/O TREVI THERAPEUTICS, INC.
195 CHURCH STREET, 14TH FLOOR
NEW HAVEN
CT
06510
0
1
0
0
Chief Medical Officer
Performance Stock Options (right to buy)
3.21
2022-09-19
4
A
0
7500
0.00
A
2022-09-19
2031-02-16
Common Stock
7500
37500
D
Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 37,500 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. On September 19, 2022, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the CANAL trial were satisfied, resulting in the vesting of the option as to the 7,500 shares of common stock.
/s/ Christopher Galletta, attorney-in-fact
2022-09-19